Expertise and resources to facilitate
Read or watch to learn more
Preclinical characterization of oncology nanomedicines
Expediting nanomedicine development
Protocols

Nanotechnology Characterization Lab

Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.

Learn about how to collaborate with the NCL.

News & Updates

The European Technology Platform for Nanomedicine (ETPN) and the EU-funded consortium ENATRANS have launched the third edition of the Nanomedicine Award to honor the best...

NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative...

The Frederick National Laboratory for Cancer Research (FNLCR) will be hosting a half-day event that will showcase technologies being developed at the National Cancer Institute...

Meet Us @

The American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition takes place in San Diego, CA, November 12-15th.